If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
=== Repair of Oxidative damage === Secondary defenses include DNA-repair systems, proteolytic and lipolytic enzymes. DNA repair enzymes include endonuclease IV, induced by oxidative stress, and exonuclease III, induced in the stationary phase and in starving cells. These enzymes act on duplex DNA and clean up DNA 3' terminal ends. Prokaryotic cells contain catalysts that modify the primary structure of proteins frequently by reducing disulfide bonds. This occurs in the following steps: (i) thioredoxin reductase transfers electrons from NADPH to thioredoxin via a flavin carrier (ii) glutaredoxin is also able to reduce disulfide bonds, but using GSH as an electron donor (iii) protein disulfide isomerase facilitates disulfide exchange reactions with large inactive protein substrates, besides having chaperone activity Oxidation of surface exposed methionine residues surrounding the entrance to the active site could function as a “last-chance” antioxidant defense system for proteins.
=== Ribosomal RNA (rRNA) sequences provide a record of the evolutionary history of all life forms === Analysis of ribosomal RNA sequences from a large number of organisms demonstrated that all extant forms of life on Earth share common structural and sequence features of the ribosomal RNA, reflecting a common ancestry. Mapping the similarities and differences among rRNA molecules from different sources provides clear and quantitative information about the phylogenetic (i.e. evolutionary) relationships among organisms. Analysis of rRNA molecules led to the identification of a third major kingdom of organisms, the archaea, in addition to the prokaryotes and eukaryotes.
Neurotransmitter receptors and receptor ionophores. Nicotinic, imidazoline I1 and I2, α2-adrenergic, glutamate NMDAr, and serotonin 5-HT2A and 5HT-3 receptors. Ion channels. Including: ATP-sensitive K+ channels, voltage-gated Ca2+ channels, and acid-sensing ion channels (ASICs). Membrane transporters. Agmatine specific-selective uptake sites, organic cation transporters (mostly OCT2 subtype), extraneuronal monoamine transporters (ENT), polyamine transporters, and mitochondrial agmatine specific-selective transport system. Nitric oxide (NO) synthesis modulation. Both differential inhibition and activation of NO synthase (NOS) isoforms is reported. Polyamine metabolism. Agmatine is a precursor for polyamine synthesis, competitive inhibitor of polyamine transport, inducer of spermidine/spermine acetyltransferase (SSAT), and inducer of antizyme. Protein ADP-ribosylation. Inhibition of protein arginine ADP-ribosylation. Matrix metalloproteases (MMPs). Indirect down-regulation of the enzymes MMP 2 and 9. Advanced glycation end product (AGE) formation. Direct blockade of AGEs formation. NADPH oxidase. Activation of the enzyme leading to H2O2 production.
Sources: en.wikipedia.org
== P == p53 - package - palindromic sequence - palmitoyl acyltransferase - Parkinson's disease - Partial cleavage stimulation factor domain - pBR322 - PCR - pedigree - peptide - peptide-transporting ATPase - peptide bond - phage - phagemid - phenotype - phenylacetaldoxime dehydratase - PhIP-Seq - phosphatase, alkaline - phosphatidylcholine 12-monooxygenase - phosphatidylcholine desaturase - phosphatidylinositol a-mannosyltransferase - phosphodiester bond - phospholipid acyltransferase - phosphonate-transporting ATPase - phosphorylation - physical map - plant calmodulin-binding domain - plasmid - plastoquinol/plastocyanin reductase - point mutation - poly-A track - polyA tail - polyacrylamide gel - polyclonal antibodies - polydactyly - polymerase - polymerase chain reaction - polymorphism - polynucleotide kinase - polypeptide - polyvinyl-alcohol dehydrogenase (acceptor) - positional cloning - positional sequencing - post-transcriptional regulation - post-translational modification - post-translational processing - post-translational regulation - PRE - precursor mRNA - primary immunodeficiency - primary transcript - primer - primer extension - probe - processivity - progesterone 5alpha-reductase - promoter - pronucleus - prostate cancer - protease - proteasome - proteasome ATPase - protein - Protein translocation - proto-oncogene - pseudobaptigenin synthase - pseudogene - pseudoknot - pseudorevertant - pulse sequence database - pulsed field gel electrophoresis - purine - PyrC leader - PyrD leader - pyrimidine
=== Federal budget projections === The Congressional Budget Office (CBO) projects budget data such as revenues, expenses, deficits, and debt as part of its "Long-term Budget Outlook" which is released annually. The 2018 Outlook included projections for debt through 2048 and beyond. CBO outlined several scenarios that result in a range of outcomes. The "Extended Baseline" scenario and "Extended Alternative Fiscal" scenario both result in a much higher level of debt relative to the size of the economy (GDP) as the country ages and healthcare costs rise faster than the rate of economic growth. CBO also identified scenarios involving significant austerity measures, which maintain or reduce the debt relative to GDP over time. CBO estimated the size of changes that would be needed to achieve a chosen goal for federal debt. For example, if lawmakers wanted to reduce the amount of debt in 2048 to 41 percent of GDP (its average over the past 50 years), they might cut non-interest spending, increase revenues, or take a combination of both approaches to make changes that equaled 3.0 percent of GDP each year starting in 2019. (In dollar terms, that amount would total about $630 billion in 2019.) If, instead, policymakers wanted debt in 2048 to equal its current share of GDP (78 percent), the necessary changes would be smaller (although still substantial), totaling 1.9 percent of GDP per year (or about $400 billion in 2019). The longer lawmakers waited to act, the larger the policy changes would need to be to reach any particular goal for federal debt.
== Example of use == Researchers often want to measure, say, medical compounds in the bodies of animals. It's hard to measure them directly, so it can be chemically joined to a radionuclide - by measuring the radioactivity, you can get a good idea of how the original medical compound is being processed. Samples may be collected and counted at short time intervals (ex: 1 and 4 hours). But they might be tested for radioactivity all at once. Decay correction is one way of working out what the radioactivity would have been at the time it was taken, rather than at the time it was tested. For example, the isotope copper-64, commonly used in medical research, has a half-life of 12.7 hours. If you inject a large group of animals at "time zero", but measure the radioactivity in their organs at two later times, the later groups must be "decay corrected" to adjust for the decay that has occurred between the two time points.
Thus, decaffeination of tea requires more care to maintain tannin content than decaffeination of coffee in order to preserve this flavor. Preserving tannins is desirable not only because of their flavor, but also because they have been shown to have anticarcinogenic, antimutagenic, antioxidative, and antimicrobial properties. Specifically, tannins accelerate blood clotting, reduce blood pressure, decrease the serum lipid level, and modulate immunoresponses. Certain processes during normal production might help to decrease the caffeine content directly, or simply lower the rate at which it is released throughout each infusion. In China, this is evident in many cooked pu-erh teas, as well as more heavily fired Wuyi Mountain oolongs; commonly referred to as 'zhonghuo' (mid-fired) or 'zuhuo' (high-fired). A generally accepted statistic is that a cup of normal black (or red) tea contains 40–50 mg of caffeine, roughly half the content of a cup of coffee. Although a common technique of discarding a short (30 to 60 seconds) steep is believed to much reduce caffeine content of a subsequent brew at the cost of some loss of flavor, research suggests that a five-minute steep yields up to 70% of the caffeine, and a second steep has one-third the caffeine of the first (about 23% of the total caffeine in the leaves).
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.